News
Menarini brings oral SERD to Europe with Orserdu okay
Menarini has secured EU approval for Orserdu, the first in a new …
19804 items found
Sales & Marketing
Celebrating 75 Years of the NHS: A timeline
Since its inception in 1948, the National Health Service (NHS) has …
News
Smartphone app cuts racial disparity in post-birth care
Remote monitoring of blood pressure in women who have just given …
News
Roche inks pipeline deals with Orionis, PeptiDream
Roche has bolstered its R&D pipeline in oncology and neuroscience …
Sales & Marketing
Sponsored
Omnichannel experts lay out keys for biopharma marketing success
Credit COVID-19, the evolution of technology, changing physician …
R&D
The SPC waiver: How do we restore the intended balance between protection and innovation?
Biosimilars promote cost-effective solutions to critical healthcare …
News
Novo Nordisk Foundation pledges €127m for cell therapy plant
The Novo Nordisk Foundation is funding the creation of a cell therapy …
R&D
Turning drug development on its head
Drug discovery is usually a goal-driven and iterative process, as …
News
EU has its first RoActemra biosimilar, from Fresenius Kabi
The European Commission has approved the first biosimilar version of …
News
FDA declines to approve needle-free epinephrine from ARS
Shares in ARS Pharmaceuticals were in freefall in pre-market trading …
News
Changes ring at Oxford Bio as ABL takeover talks progress
UK contract development and manufacturer organisation (CDMO) Oxford …
Sales & Marketing
Sponsored
Company Profile: Healthcare Consultancy Group
CEO/President Matt D’Auria Headquarters New York US (HQ), Connecticut …
R&D
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...
Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Patients
Deep Dive: Patients & Partnerships 2024
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Sales & Marketing
Sponsored
Seeking a single source of truth: Standardisation of the dat...
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
EHS&S for Biopharma & Pharma Summit
Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities
R&D
Partner Content
Proteomic Based Drug Discovery Summit 2025
Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & T
